The ZEST Trial - A double-blind, placebo-controlled trial of Zoloft's Effects on Symptoms and survival Time in Advanced Cancer by Azim, Syed
Biostatistics Collaboration of Australia 
University of Sydney 
 
 
 
 
Work  Placement  Project Portfolio 
 
Containing: Preface, Project Report for 
Units of study: WPPC 
 
 
 
 
Student name: Syed Azim 
Student ID: 306117363 
 
 
 
 
 
Sydney, November 2008 
Does a mild anti-depressant improve quality of life in patients with advanced 
cancer?  
 
 
 
The ZEST Trial 
 
A double-blind, placebo-controlled trial of 
ZRORIW¶VEffects on Symptoms and survival Time in 
Advanced Cancer 
 
 
 
 
 
 
 
 
NHMRC Clinical Trials Centre, University of Sydney 
NSW Cooperative Oncology Group 
Preface
Background
Diagnosis and proper treatment for patients with depression can improve their quality of 
life. The physical symptoms of depression include: change in appetite/weight, sleep 
disturbance, fatigue, loss of energy, diminished ability to think or concentrate etc. 
Depression is a common scenario in cancer patients especially in advanced stage. It
impacts on mental health and can influence the medical course of the patient. Effects on 
mental health include: undermining the will to live, increasing desire to hasten death etc. 
Depression can accelerate the progression of cancer disease and consequently influence a 
patient’s survival. 
A number of small trials have been conducted which demonstrated that conventional 
antidepressants may improve fatigue and QoL in people with cancer and major 
depression. A large trial is needed to assess a simple, safe and effective antidepressant in 
people with advanced cancer who feel anxiety, depressed or tired but do not have major 
depression. Hence the ZEST trial was undertaken.
The ZEST trial is a randomized, double-blinded, multi-center trial of sertraline versus 
placebo using appropriate patient rated outcome measures where the primary objective is 
to determine the effect of a modern antidepressant (sertraline) on feelings of depression, 
anxiety, fatigue and lack of energy. The secondary objective is to determine the effect on 
overall survival.
In February 2006 in response to a recommendation from the trial’s Independent Safety 
Data Monitoring Committee the trial was suspended.  
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Reflections on learning 
Through this project I have learnt how to implement statistical methods in real life 
analysis. We have covered many statistical methods in the BCA courses but in this 
project I have learnt how to apply these methods in practical problems. This project gave 
me a good opportunity to obtain experience of data analysis using statistical software 
STATA. Now I have a better understanding of randomized controlled trials and how to 
analyze data from a randomized trial. After completion of this project, I have a strong 
belief that BCA courses are designed to solve practical problems and now I think I can 
analyze all sorts of data in future.
Student’s role
As a student my role was to prepare and manipulate the raw data for analysis, and 
subsequently apply appropriate statistical methods to analyze the data according to the 
study objectives. Survival analysis methods such as the log-rank test and cox proportional 
hazards models were used to analyze time to event outcomes. Generalized Estimating 
Equations (GEE) were used for the primary QoL analysis. This method adjusts for the 
intra-subject correlation owing to subjects having repeated QoL measurements. I had to 
carry out related data management tasks defined by the project supervisor. The analysis 
was carried out using STATA and SAS software. I would make proposals to my 
supervisor concerning which statistical methods should be applied to address the study 
objectives. I also prepared the layout of the tables and figures. My supervisor would then 
provide feedback which I acted upon. Several iterations of the analysis and text for the 
trial results report were conducted until the work was finalized. The final analysis was 
completed within 3 months of the trial close-out date according to the study protocol.
Before analysis could commence the data needed to be cleaned. Through this task I have 
gained insight into the types of data errors that occur and appreciate the importance of 
running data checks and queries prior to analysis. The statistical analysis included: data 
manipulation, calculating scores, running appropriate statistical procedures, interpreting 
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results and transcribing results into a table for presentation.  To do this I had to apply my 
knowledge and understanding of the theory and methods learnt during the BCA course.  
Communication skills 
During this project I had regular meetings with the project supervisor to discuss 
associated problems and issues. All through this project I had one regular weekly face to 
face meeting and other communications were through e-mail and telephone when 
necessary.
Team work 
I worked on this project under direct supervision of the project supervisor. We liaised 
with the trial investigators to discuss results and additional analyses when necessary. 
There were other people involved in this project but no direct involvement with them was 
necessary.
Ethical considerations 
There were ethical considerations for this project. The data were collected and finalized 
before the analysis was conducted. Patients were de-identified using ID’s and no other 
personal information was present. The ZEST trial obtained ethics approval before 
randomization of patients onto the trial began.  All sorts of actions were taken to ensure 
privacy and confidentiality of data. The trial protocol was approved by human-research 
ethics committees at all participating institutions. The data will be stored on the NHMRC 
CTC network at least for 10 years. 
Page 3 of 36 
Workplace Project Portfolio
Project title  
Does a mild anti-depressant improve quality of life in patients with advanced cancer?  
Location and dates 
NHMRC Clinical Trials Centre, University of Sydney. 
August 2008-November 2008. 
Aim
To determine if a modern antidepressant (sertraline) improves subjective well-being and 
survival in a broad cross-section of people with advanced cancer who feel depressed, 
anxious, tired or lack energy, but do not have major depression. 
Objectives
To determine the effects of a modern antidepressant (sertraline) on 
1. Feelings of depression, anxiety, fatigue and lack of energy (primary objective) 
2. Overall survival (secondary objective) 
3. Adverse events (tertiary objective) 
4. Compliance (tertiary objective) 
Study design 
Multicentre, double-blind, placebo-controlled trial with central randomization, stratified 
to balance for institution, gender, future cytotoxic treatment anticipated (yes or no) and 
performance status (ECOG 0-1 or 2). 
Population
Simple eligibility criteria based on the uncertainty principle: people with advanced cancer 
in whom there is doubt about the benefits of treatment with antidepressants. 
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Study treatments 
Sertraline 50mg, one tablet once daily by mouth with or without food  
or
Identical placebo, one tablet once daily by mouth with or without food. 
Sertraline (Zoloft) is a selective inhibitor of serotonin reuptake (SSRI). It has little or no 
effect on reuptake of noradrenaline or dopamine. It has little or no effect on receptors for 
serotonin, noradrenaline, dopamine, acetyl choline, Gamma amino butyric acid (GABA), 
Histamine, or benzodiazepines. It is of proven benefit in major depression, obsessive 
compulsive disorder, panic disorder. 
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Project Report
Introductionȱȱ
Cancer is a common disease in Australia. About 1 in 4 Australians develop advanced 
cancer and over 33,000 Australians die from advanced cancer each year.1 About 1 in 5 
people with cancer have major depression during their illness;2- 4 symptoms of depression 
in the absence of major depression are even more common.5- 7 In a sample of 1109 
community oncology out-patients, 35% had clinically significant depression based on the 
Zung Self-Rating Depression Scale; the incidence of depression increases with advanced 
stage, physical debilitation and pain.4 Fatigue is highly prevalent among people with 
advanced cancer. In a sample of over 1000 patients with advanced cancer assessed with 
the Functional Assessment of Cancer Therapy – General (FACT -G), fatigue was 
reported by about 75% of patients; sadness and anxiety were each reported by about 60% 
of patients.8 Self-ratings of depression, anxiety and fatigue are closely correlated with one 
another and with global ratings of quality of life in people with advanced cancer.7 Their 
causes are multi-factorial and difficult to separate.9, 10 
Depressed mood, fatigue, and global quality of life are also highly significant predictors 
of survival in advanced cancer.6, 7, 11 The simple explanation for this association with 
survival duration is that people closer to death feel worse. However, two small 
randomized trials have shown substantial survival benefits with interventions aimed at 
improving psychological well-being.12-14 These findings suggest that a much more 
interesting alternative is worth testing: that improving psychological well-being prolongs 
survival in advanced cancer. Large randomized trials testing this hypothesis are ongoing 
in Canada and Australia.15
Antidepressant drugs might improve psychological well-being in people with advanced 
cancer. Systematic reviews of randomized trials demonstrate the effectiveness, 
tolerability and modest side effects of conventional antidepressants (e.g. sertraline) in 
major depression with coexisting physical illness (18 trials, 838 patients).16 Four small 
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randomized trials suggest that conventional antidepressants are effective and well-
tolerated in people with cancer and major depression, and that they may also improve 
fatigue and overall quality of life.17- 20
Antidepressants, especially selective serotonin reuptake inhibitors – are prescribed 
widely, not only for their standard indicators, but also for a wide range of subthreshold 
anxiety and depression disorders, especially in patients with comorbidity. 
21Antidepressants have been used widely in patients with cancer, and those with other 
chronic diseases, as management for chronic pain, insomnia, chronic fatigue, and anxiety 
or distress associated with physical illness.
We aimed to find out whether an established antidepressant (sertraline) improves well-
being in patients with advanced cancer who feel depressed, anxious, tired or lack of 
energy, but do not have major depression. We postulated that sertraline might improve 
these features of health-related quality of life and increase overall survival by helping 
patients to cope better with their illness and treatment. 
Objectiveȱȱ
The objective of this study was to determine the effects of a modern antidepressant 
 (sertraline) on feelings of depression, anxiety, fatigue and lack of energy, overall 
survival, adverse events, compliance and reasons for discontinuation. 
Hypothesesȱ
That a modern antidepressant (sertraline) will:   
1) Improve depression, anxiety, fatigue, lack of energy and other aspects of health-
related quality of life and
2) Improve overall survival by helping people to deal better with their illness and 
treatment.
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Methodsȱ
Descriptionȱofȱtrialȱdesignȱȱ
The ZEST trial was a multicentre, double-blind, placebo-controlled, centrally randomised 
trial that was stratified for institution, sex, anticipated future cytotoxic treatment (ie, yes 
vs no) and Eastern Cooperative Oncology Group performance status (ECOG PS 0-1 vs 2) 
by use of a computerised minimisation algorithm.  Randomisation was done over the 
telephone by the study coordinator at the NHMRC Clinical Trials Centre, University of 
Sydney, NSW, Australia, after confirmation of each patient’s eligibility. 
The trial protocol was approved by human-research ethics committees at all participating 
institutions.
Participantsȱ
Eligible patients were those with advanced cancer, in whom there was doubt about the 
benefits of treatment with antidepressants. Inclusion criteria included: advanced cancer 
defined by the presence of metastatic disease and treatment with palliative intent; a self 
rating baseline score 4/10 for depression, anxiety, fatigue or lack of energy (here 4 
means moderate); ECOG performance status 0-2; life expectancy of >3 months; serum 
creatinine <200 micromol/L and bilirubin <30 micromol/L within 28 days of 
randomization; able to complete baseline quality of life instruments; availability and 
willingness for follow-up; written informed consent. Women of childbearing potential 
must need to take adequate contraceptive precautions. 
Exclusion criteria included: major depression; delirium as detected by the Confusion 
Assessment Method; coexisting conditions contraindicating treatment with serotonin 
reuptake inhibitors; history of hypersensitivity to sertraline; diagnosis of carcinoid 
tumour; past history of schizophrenia or bipolar affective disorder; treatment with 
antidepressants (including St John’s Wort) or procarbazine within the last 4 weeks; 
pregnant or lactating women; treatment with tramadol in the last 7 days. (ZEST 
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participants should not use Tramadol because of the possibility of an interaction causing 
the serotonin syndrome). 
Recruited oncologists were instructed that any potential participants whom they thought 
might have major depression should be referred to the psychiatrist co-investigator at their 
institution.  If the psychiatrist thought that there was a definite indication for 
antidepressants, the patient was treated off-study and not recruited to the trial. 
Studyȱtreatmentȱ
Study treatment was with either sertraline 50mg, one tablet daily by mouth or with a 
placebo of identical appearance (both provided by Pfizer). Study treatment was to 
continue indefinitely in the absence of prohibitive toxicity. The decision to stop study 
treatment because of adverse events, or to recommence it if they resolved, was at the 
discretion of the patient and physician. Dose adjustments were not recommended. 
Discontinuation was to be done gradually if possible, by reducing the daily dose to 25mg 
(half a tablet) for 1 week before stopping completely.  
Concomitant anticancer and supportive treatments (including psychological, psychiatric, 
social and other supports) were used according to standard local practice. Participants 
who developed symptoms of major depression were to be referred to the psychiatrist co-
investigator at that centre. If the psychiatrist believed that there was a definite indication 
for antidepressants, then the ZEST Study Drug was discontinued and patients were 
started on antidepressants under the psychiatrist’s supervision. 
Studyȱassessmentȱȱ
Symptoms, well-being and quality of life were self-rated by patients at weeks 0, 4, and 8 
with a booklet including necessary instruments. The booklet was completed by the study 
participants in the clinic while they were waiting to see their oncologists.  Study nurses 
checked the booklets and asked participants to complete missing responses. Missing 
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responses were therefore infrequent. The forms were masked from identification and 
patients’ study numbers were used to link the forms to patients. 
The Centre for Epidemiologic Studies Depression Scale (CES-D, 20 items) is a validated 
measure for identifying depression in the general population. The Hospital Anxiety and 
Depression Scale (HADS, 14 items) is a validated measure of anxiety and depression in 
the medically ill people.22 The Functional Assessment of Cancer Therapy General and 
Fatigue scales are validated measures of the broad symptomatology (FACT-G, 27 items) 
and fatigue (FACT-F, 13 items) associated with cancer.  The Fatigue scale was used for 
this study. The Patient Disease and Treatment Assessment Form (Patient DATA Form, 
24 items) is a single-page measure rating 17 symptoms and 7 aspects of well-being on 
numeric ratings scales from 0 to 10.  
For CES-D we analyzed all 20 questions on the form to derive an overall depression 
scale. For HADS, we analyzed all 14 questions; these questions were divided into two 
groups to derive overall scores for anxiety and depression.  From Patient DATA form, 3 
questions were analyzed for fatigue, anxiety and depression. For FACT-F, all 13 
questions were analyzed to derive an overall score for fatigue. 
When calculating overall scores it was necessary to reverse the scores for some items so 
that the direction of the scales was consistent across all items. 
Clinicians assessed performance using the ECOG and Karnofsky scales.22 ECOG and 
Karnofsky scales were used to obtain a rating of the patient’s health performance (i.e., 
level of functioning and disability) at baseline.
Plannedȱsampleȱsizeȱ
The intended sample size was 440 patients, recruited over 3 years and followed for 1 
additional year. This was calculated based on a minimum clinically important difference 
of 10 points and a standard deviation of 25 on a 100-point scale (for depression, fatigue, 
lack of energy) 24-26 with a two-sided alpha (p-value) of 0.01 (adjusted down for multiple 
comparisons).  Two hundred patients per arm would give over 90% power to detect the 
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superiority of antidepressants over placebo in improving QoL (depression, anxiety, 
fatigue) and would detect a 50% improvement in median survival time (eg 8 to 12 
months).
Plannedȱinterimȱanalysesȱȱ
Interim analyses was planned to be performed on data collected 12 weeks after 
randomization of the 150th and 300th patients focusing on safety (frequency and severity 
of adverse events), feasibility (completion of 8 weeks of therapy, follow-up at 8 weeks) 
and survival. The results were to be reported to an independent Safety and Data 
Monitoring Committee (DSMC). The DSMC is guided by conservative notional 
significance levels of 2p = 0.003. Based on these results, the DSMC would advise the 
Trial Management Committee whether to stop, expand or modify the trial.
Interim analysis was conducted by another statistician and final analysis was conducted 
by me.   
Statisticalȱanalysesȱ
All efficacy analyses were done by intention to treat and included all patients, regardless 
of whether they were taking their allocated treatment. Toxicity analyses included all 
patients who had taken study treatment within the past 30 days. Reported p-values are 2-
tailed, and should be interpreted conservatively because they have not been adjusted for 
multiple comparisons.  
Qualityȱofȱlife:ȱ
The primary measures for each quality of life outcome were the: CES-D for depression, 
HADS-A for anxiety and FACT-F for fatigue. Alternate measures of these outcomes, for 
example the HADS-D for depression and items from the Pt DATA Form, were used for 
corroboration .The primary analysis was a comparison of the treatment groups based on 
scores at 4 and 8 weeks using generalized estimating equation (GEE) regression models 
with treatment group and baseline scores as covariates. An exchangeable correlation 
structure was used for the GEE model. The randomization procedure was stratified to 
balance for center, grade, future cytotoxic treatment and ECOG performance status. 
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Hence it is not necessary to adjust for these factors in the multivariate analysis, as they 
should have been and were balanced between the two treatment arms. For the repeated 
measures analysis time was not included as a covariate which effectively meant that the 
treatment effect estimate and least square adjusted mean scores for each treatment group 
were calculated based on the average of the 4 and 8 week scores for each subject. The 
advantage of this is that using an average of 2 repeated measurements is more reliable 
and reduces measurement error compared to using a single measurement. Since time was 
not a covariate we did not need to include any random effects in the model (i.e., modeling 
time as a random effect allows the effect of time on QoL to be patient-specific), hence a 
GEE model was sufficient. A suitably specified random effects mixed model would give 
similar results and conclusions. For this analysis scores for all aspects of health-related 
QoL were linearly transformed to a scale from 0 to 100 where 0 is the best and 100 worst. 
Patients required a score at either 4 or 8 weeks or both to be included in this modeling 
analysis. Patients that only had 1 of the 4 and 8 week time points for the QoL scores are 
still included in the GEE analysis. These patients contribute to the estimation of 
parameter estimates but not the correlation matrix which contributes to the estimation of 
standard errors for parameter estimates. 
Secondary measures of effect included the proportions of people having an improvement 
greater than 20% of the response range (eg 2 points on a scale from 0 to 10) from 
baseline to weeks 4 and 8. Fisher’s exact test was used to compare major improvement 
between treatment groups due to low cell counts (<5). The Fisher’s exact test is 
conservative since the row and column marginal totals are allowed to vary. An additional 
sensitivity analysis was later conducted using the conditional binomial exact test which 
fixes the treatment column totals; conclusions were unchanged.  
When calculating QoL scores patients were required to complete at least 66% of the 
items which constituted that dimension; otherwise the score was set to missing.  
Safetyȱandȱadverseȱevents:ȱ
Safety and adverse events were categorized and graded according to version 2 of the US 
National Cancer Institute common toxicity criteria.
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For each patient the maximum severity (grading from 0 to 4) experienced for each of the 
11 adverse events was determined. The proportions of patients with 0, 1, 2, 3 and 4 as 
their worst grade for each adverse event were tabulated by treatment group. Patients not 
experiencing a specific adverse event were graded as zero for that event. Patients with no 
data for all the adverse events (i.e., missing) were excluded. Due to the nature of the 
follow-up visits and to ensure that no adverse events that could have been attributed to 
treatment are missed, the events reported during assessments performed up to the 
assessment following the treatment termination date plus 30 days were included. Adverse 
events occurring after this time are not likely to be related to treatment. 
For the laboratory analysis patient’s biomarkers (WCC, Lymphocytes, Hemoglobin etc) 
were also graded using cutoffs from version 2 of the US National Cancer Institute 
common toxicity criteria. Analysis of patient’s blood levels will determine whether there 
is an excess of toxicity in the active treatment arm. Only biomarker data collected during 
the first year of follow-up was used for this analysis. Laboratory tests performed up to the 
treatment termination date plus 30 days and additionally results from the first laboratory 
test done after this date were included. Toxicities occurring after this time are not likely 
to be related to the treatment. Cutoffs indicate which levels are within normal range, and 
above or below upper/lower limits of normal ranges. An extreme biomarker reading (e.g. 
 5 x ULN, Upper Limit Normal) will have a severe grade (e.g. grade IV).  Laboratory 
readings within normal limits receive a grade of zero. Values outside the normal limits 
receive a grade ranging from 1 to 4 depending on how abnormal the reading is. For 
example for Hemoglobin the extreme grade (i.e., grade 4) is 6.5g/dL, grade 3 is 6.5 - 
8.0 g/dL, grade 2 is 8.0-10.0 g/dL, grade 1 is Lower Limit Normal (LLN)-10.0 g/dL 
and grade 0 if it is  LLN.
The Mann-Whitney U test [also called the Mann-Whitney-Wilcoxon rank-sum test] was 
used to test for differences in worst grades obtained between treatment arms for the 
adverse events and laboratory analysis. This test was used because it is a non-parametric 
test for assessing whether two treatment groups come from the same distribution. Due to 
the skewed distribution of the adverse event and toxicity grades this test was appropriate 
for this analysis. As it is a non- parametric test, it does not require normality or equality 
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of variance. This test uses the ranks of the data rather than their raw values to calculate 
the p-value.
Overallȱsurvivalȱandȱtreatmentȱfailure:ȱ
The secondary endpoint overall survival was calculated from the date of randomization to 
date of death for any cause.
The primary analysis for effects on survival was an unadjusted log-rank test. The log- 
rank test is used to compare the survival distributions of groups and is widely used in 
clinical trials to establish the efficiency of a new treatment compared to the current 
standard treatment. 23 The log-rank test was used because an unadjusted analysis was 
required for the primary analysis and the log-rank method provides the most powerful 
test. The log-rank method takes into consideration the area between the curves on a 
Kaplan-Meier plot and provides the most pure measure of statistical significance. In 
addition the log-rank test does not make any assumptions unlike the proportional hazards 
cox model which constrains the relative effect over time between groups to be constant. 
Multivariable Cox’s proportional-hazards models were used for secondary analyses 
accounting for other baseline factors. The multivariable analysis was conducted to 
confirm the results of the unadjusted log-rank test. The adjusted analysis controls for any 
minor chance imbalance in baseline characteristics between the treatment arms. A series 
of univariate cox models were fitted as a preliminary step. Baseline variables with p-
value 0.05 in univariate analysis were considered for inclusion in the multivariable 
analysis. The multivariable analysis was conducted by running a backward elimination 
procedure, and selecting from the pool of variables with p-value 0.05 in univariate 
analysis. Treatment was forced into the model and only significant (p0.05) baseline 
covariates were retained. This determined the final model.  
A caveat of this approach for the multivariable analysis is that only variables that were 
significant in univariate analysis were considered for inclusion in the backward selection 
procedure. It is possible that variables were excluded which become significant after 
adjusting for other variables. The variables which were not considered were balanced 
between treatment arms anyway and were highly non-significant in univariate analysis. 
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So, we doubt that the conclusion would have changed if all variables were entered into 
the model building procedure.  
For univariate Cox models most of the covariates had no missing values. For body weight 
there were 5 missing values and all QoL scores had 3 missing values except FACT-F 
which had only 2 missing values. For all the covariates selected for inclusion in the final 
model, there were no missing values.  
Treatment failure was defined as time to permanently discontinuing study medications. 
Temporary stopping was allowed and was not counted as a failure. To compare treatment 
failure between the two treatment arms the log-rank test was used.
A Cox model was also used to obtain a hazard ratio and 95% CI to obtain a measure of 
effect for the risk of terminating treatment for sertraline patients relative to placebo 
patients.
Kaplan-Meier curves were constructed for all time-to-event analyses. For all Cox models 
the proportional – hazards assumption was checked using plots of schoenfeld residuals. 
This involves plotting residuals for each covariate versus follow-up time. Schoenfield 
residuals differ from the usual way residuals are regarded for a model (one residual for 
each case) in that there is a residual for each explanatory variable included in the model. 
Plots of these residuals versus time can reveal departures from the proportionality 
assumption. These residuals are also used in the Harrell-Lee test of proportional hazards 
which uses the correlation coefficient between the residuals and rank of the times.    
Complianceȱ
Compliance with study treatment was monitored by counting tablets. 
ȱ
ȱ
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ȱResultsȱȱ
Twelve weeks after the 150th patient was recruited interim analysis was conducted on the 
first 150 patients as planned. This revealed a trend towards shorter survival in the 
sertraline group than in the placebo group (p = 0.04, median follow-up of 15 months) and 
in response to a recommendation from the trial independent DSMC, recruitment was 
suspended. The results of this report are based on the 189 patients, recruited from July, 
2001, to February, 2006, which comprise the final trial cohort. Figure 1 shows the trial 
profile.
Figure 1: Zest Trial Profile
189 patients randomised 
94 assigned placebo 95 assigned sertraline 
2 Deaths 0 Death 
4 weeks
93 alive
74 still on therapy 
78 completed QoL 
4 weeks
94 alive 
86 still on therapy 
85 completed QoL 
8 weeks
89 alive 
64 still on therapy 
64 completed QoL 
Close-out: June 06
28 alive 
4 Deaths 3 Deaths 
8 weeks
91 Alive 
74 still on therapy 
81 completed QoL 
61 Deaths 58 Deaths
Close-out: June 06
33 alive 
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Patients still on study treatment were contacted, informed of the results, and given the 
option of stopping or continuing study treatment whilst definitive analyses were done 
including all 189 patients and longer follow-up and data for health related QoL. Blinding 
was maintained. 
The following results (Tables 1 & 2) are based on the 189 patients. 
Table 1: Baseline characteristics by treatment group 
Sertraline
(n = 95) 
Placebo
(n = 94) 
   Total 
 (n = 189) 
Age
<50 12 (12%) 3 (3%) 15 (8%) 
50-59 18 (19%) 24 (26%) 42 (22%) 
60-69    34 (36%) 33 (35%) 67 (36%) 
70+ 31 ((33%) 34 (36%) 65 (34%) 
Gender
Male 55 (58%) 56 (60%) 111 (59%) 
Female 40 (42%) 38 (40%) 78 (41%) 
ECOG
0 13 (14%) 8 (9%) 21 (11%) 
1 60 (63%) 67 (71%) 127 (67%) 
2 22 (23%) 19 (20%) 41 (22%) 
KPS
50 1 (1%) 1 (1%) 2 (1%) 
60 5 (5%) 3 (3%) 8 (4%) 
70 16 (17%) 20 (21%) 36 (19%) 
80 48 (51%) 41 (44%) 89 (47%) 
90+ 25 (26%) 29 (31%) 54 (29%) 
Cancer Stage
I 10 (11%) 6 (7%) 16 (9%) 
II 18 (20%) 20 (22%) 38 (21%) 
III 23 (26%) 22 (25%) 45 (25%) 
IV 38 (43%) 41 (46%) 79 (45%) 
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Sertraline
(n = 95) 
Placebo
(n = 94) 
   Total 
 (n = 189) 
Primary Cancer Site : 
Lung 19 (20%) 10 (11%) 29 (15%) 
Breast 17 (18%) 15 (16%) 32 (17%) 
Prostate 10 (11%) 16 (17%) 26 (14%) 
Colorectal 8 (8%) 21 (22%) 29 (15%) 
Other 41 (43%) 32 (34%) 73 (39%) 
Involved Sites : 
Loco-regional 53 (56%) 48 (51%) 101 (53%) 
Bone Metastasis 36 (38%) 32 (34%) 68 (36%) 
Lung/Pleural Metastasis 34 (36%) 29 (31%) 63 (33%) 
Brain Metastasis 4 (4%) 2 (2%) 6 (3%) 
Other Distant Metastasis 17 (18%) 22 (24%) 39 (21%) 
Previous Anticancer Therapy : 
Previous surgery  55 (58%) 59 (63%)  114 (60%) 
Previous radiation therapy 52 (55%) 40 (43%) 92 (49%) 
Previous/Current endocrine therapy 32 (34%) 30 (32%) 62 (33%) 
Previous/Current chemotherapy  78 (83%) 78 (83%) 156 (83%) 
Current chemotherapy 54 (57%) 57 (61%) 111 (59%) 
Previous interferon or interleukin  0 (0%) 0 (0%) 0 (0%) 
Current Opioid use  31(33%) 18 (19%) 49 (26%) 
Patient Symptoms : 
Shortness of Breath 39 (41%) 35 (37%) 74 ( 39%) 
Eating 15 (16%) 13 (14%)  28 (15%) 
Appetite 38 (40%) 28 (30%) 66 (35%) 
Trouble swallow 7 (7%) 8 (8%)   15 (8%) 
Dry Mouth  25 (26%) 10 (11%)   35 (19%) 
Weight Loss 29 (31%) 21 (22%)   50 (26%) 
Fatigue 85 (89%) 87 (92%)   172 (91%) 
Life Expectancy (months) : 
 < 6 6 (11%) 3 (5%)    9 (8%) 
6-9 21 (37) 30 (52%)  51 (45%) 
10-15 18 (32%) 13 (22%) 31 (27%) 
16-24 10 (18%) 10 (17%) 20 (17%) 
24+ 1 (2%) 2  (4%) 3 (3%) 
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Table 2: Baseline blood levels and time to advanced disease (median [IQR]) 
Sertraline
(n = 95) 
Placebo
(n = 94) 
   Total 
 (n = 189) 
Blood Test : 
WCC (x109/L) 6.4 (4.3- 7.8) 6.55 (5.1-8.1) 6.4 (4.8-8) 
Lymphocytes (x109/L) 1.4 (1-2) 1.4 (1-1.9) 1.4 (12) 
Hemoglobin (g/dL) 12.3 (10.9-13.4) 12.25 (11.5-13.6) 12.3 (11.2-13.5) 
Platelets (x109/L) 232 (182-320) 252 (186-313) 244 (185-319) 
Serum albumin (g/L) 37.31 (4.79) 37.85 (4.78) 37.58 (4.78) 
Serum sodium (mmol/L) 138 (136-140) 139 (137-141) 139 (137-141) 
AST (IU/L) 25 (18-34) 23 (18-31) 25 (18-32) 
ALT (IU/L) 22 (17-35) 21 (16-30) 21 (16.5-30.5) 
Gammagt (IU/L) 38 (23-93) 46 (24-99) 44 (23-98) 
ALP (IU/L) 100 (80-155) 103.5 (81-145) 102 (81-152) 
CRP(x109/L) 12 (5-35) 9 (4-23.5) 10 (5-29) 
Creatinine (ȝmol/L) 77 (63-98) 74 (56-91) 75 (60-95) 
Time to Advanced Disease (median) 7.8 (0-42.9) 9.4 (0-36.1) 9.0 (0-38.3)
Descriptionȱofȱoverallȱpopulationȱȱ
Tables 1 & 2 show the baseline characteristics of the participants. Most of the 
participants are male (59%) and aged persons (60+). Seventy eight percent of participants 
had an ECOG grade of less than or equal to 1 which is good performance status (i.e., able 
to carry out activities).  One hundred and forty three (76%) patients had KPS of 80-90 
meaning normal activity with/without effort; some/minor signs or symptoms of disease. 
The lowest number of participants belonged to cancer stage 1 (9%) and highest in stage 4 
(45%). A large number of patients were currently having chemotherapy (59%). Just over 
half of the patients had less than 9 months life expectancy (53%).  
Differencesȱbetweenȱtreatmentȱgroupsȱ
The randomization was effective with some minor exceptions.  In the sertraline group 
there are more participants with lung cancer, fewer with colorectal cancer, and more 
using opioids at baseline than the placebo group. 
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DescriptionȱofȱQoLȱforȱtotalȱpopulationȱ
Table 3 shows participants’ QoL self-ratings at baseline. Forty seven (26%) of 189 
patients had scores consistent with clinical depression according to the CES-D.  Twenty 
five (13%) of 189 patients had scores consistent with clinical anxiety according to the 
HADS-A. Ninety three 93 (50%) of 189 patients had scores consistent with moderate or 
worse fatigue according to the FACT-F. 
Table 3: Baseline ratings of depression, anxiety and fatigue 
Aspect, instrument and 
interpretation 
Scores Sertraline
(N = 95)
n (%) 
Placebo
(N = 94) 
n (%) 
All
(N = 189)
n (%) 
Depression 
CES-D
Unlikely <15 50(53%) 43(47%) 93(50%) 
 Possible 15-19 19(20%) 27(29%) 46(25%) 
 Likely >19 25(27%) 22(24%) 47(26%) 
HADS-D 
 Normal 0-7 72(78%) 70(75%) 142(76%) 
 Subclinical 8-10 12(13%) 17(18%) 29 (16%) 
 Clinical >10 9(9%) 6(7%) 15 (8%) 
Pt-DATA Form
None 0 24 (26%) 23(26%) 47(26%) 
 Mild 1-3 34(36%) 40(44%) 74(40%) 
 Moderate 4-6 29(31%) 21(23%) 50(27%) 
 Severe 7-10 7(7%) 6(7%) 13(7%) 
Anxiety
HADS-A 
 Normal 0-7 66(70%) 66(72%) 132(71%) 
 Subclinical 8-10 14(15%) 15(16%) 29(16%) 
 Clinical >10 14(15%) 11(12%) 25(13%) 
Pt-DATA Form 
 None  0 21 (23%) 19 (21%) 40 (22%) 
 Mild 1-3 31 (34%) 38 (42%) 69(38%) 
 Moderate 4-6 30 (32%) 25 (28%) 55(30%) 
 Severe 7-10 10 (11%) 8 (9%) 18(10%) 
Fatigue
FACT-F
 None 0-17 22(23%) 30(33%) 52(28%) 
 Mild 18-23 23(24%) 19(21%) 42(22%) 
 Moderate 24-43 45(48%) 41(44%) 86(46%) 
 Severe 44-52
5(5%) 2(2%) 7(4%) 
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Aspect, instrument and 
interpretation 
Scores Sertraline
(N = 95)
n (%) 
Placebo
(N = 94) 
n (%) 
All
(N = 189)
n (%) 
Pt-DATA Form
 None  0 0(0%) 1(1%) 1(1%) 
 Mild 1-3 9(10%) 8 (9%) 17(9%) 
 Moderate 4-6 56(59%) 53(59%) 109(59%) 
 Severe 7-10 29(31%) 28 (31%) 57(31%) 
DescriptionȱofȱeffectsȱofȱtreatmentȱonȱQoL:ȱ
In both treatment groups patients completed QoL at baseline. In the sertraline group at 4 
weeks 78 completed QoL, 70 of which were still taking study medication. At 8 weeks 64 
completed QoL questionnaires, 59 of which were still on treatment.  
In the placebo group at 4 weeks 84 patients completed QoL questionnaires of which 82 
were still on treatment. At 8 weeks 80 patients completed QoL questionnaires of which 
74 were still on treatment.  
Table 4: Effects of sertraline on patients’ self-ratings of depression, anxiety and 
fatigue
Adjusted mean scores at 4 and/or 8 weeks Number of patients with major 
improvement
Sertraline Placebo
n = 78 n = 84
Benefit 95% CI P value* Sertraline
n = 78
Placebo 
n = 84
P value† 
Depression 
CES-D 23.29 23.68 0.38 -2.66   3.42 0.81 3 6 0.33 
HADS-D 24.05 25.44 1.39 -2.18   4.96 0.45 1 4 0.21 
Pt-DATA  19.13 21.11 1.98 -3.78   7.75 0.50 18 13 0.43 
Anxiety 
HADS-A 23.85 25.81 1.96 -1.56   5.47 0.28 6 3 0.50 
Pt-DATA  21.74 22.62 0.89 -4.47   6.24 0.75 15 14 1.00 
Fatigue 
FACT-F 42.90 43.20 0.30 -4.29   4.89 0.90 8 3 0.21 
Pt-DATA  49.61 51.07 1.47 -4.57   7.51 0.63 16 17 0.85 
* Generalised Estimating Equation 
† Fisher’s Exact Test  
From the above table it is clear that sertraline has little effect on self-ratings of 
depression, anxiety or fatigue, with no significant differences between groups at 4 and 8 
weeks.  For example, in the sertraline group 3 patients have major improvement 
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according to CES-D and 6 patients in placebo group. Also for anxiety according to the 
HADS-A patients in the sertraline group score on average 1.96 points higher than placebo 
patients, but this improvement is not statistically significant (p=0.28). 
95% CI’s for every outcome measure excluded the minimum clinically important benefit 
of 10 points on a 100-point scale. 
Figure 2: Survival by treatment group 
Logrank test: p=0.09
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Figure 2 : Survival by Treatment Group
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At the final analysis (n = 189, median follow-up 19 months, range = 12 – 36 months),
overall survival did not differ significantly between treatment groups (unadjusted hazard 
ratio 1.34 [CI: 0.95- 1.9], log-rank p =0.09, Figure 2). Overall, 128 patients died (Figure
1).
Table 5 shows the results of univariable and multivariable analysis examining the 
association between baseline covariates and survival. In univariate analysis out of 22 
covariates (excluding sertraline) only 12 were found significant and considered for 
Page 24 of 36 
multivariable analysis. From the 13 covariates (with sertraline forced) entered into the 
backward elimination procedure, 6 were remained. 
Table 5: Factors associated with survival in Cox’s proportional-hazards model
Univariate Cox† Multivariate Cox †Risk factors* n (%) 
HR 95% CI p-value HR 95% CI p-value 
Sertraline 95 (50) 1.34 0.95    1.90 0.096 1.31 0.90   1.91 0.15 
Age > 65 92 (49) 1.26 0.89    1.79 0.19 
Male 111(59) 1.47 1.02    2.13 0.04 
Liver or brain metastatic 
disease
65 (34) 1.63 1.13    2.36 0.01 1.64 1.11    2.41 0.01 
Time from initial diagnosis 
to adv disease <9 month 
94 (50) 1.42 1.00  2.01 0.05 
Primary Site: Lung 29 (15) 2.14 1.38    3.32 0.001 2.43 1.54    3.83 <0.01 
Baseline treatment: 
Opioids 49 (26) 2.05 1.39    3.03 <0.01 1.97 1.29    2.99 <0.01 
Steroids 21 (11) 1.45 0.87    2.42 0.16 
Previous/Current  
chemotherapy  
156 (83) 1.84 1.12    3.04 0.02 1.99 1.17    3.40 0.01 
Baseline bloods: 
Haemoglobin <12.3 g/L 94 (50) 1.58   1.11  2.24 0.011 
Lymphocytes <1.5 x109/L 99 (52) 1.43 1.01    2.02 0.045 1.50 1.04    2.16 0.03 
Albumin <38 g/L 92 (49) 1.44 1.02    2.04 0.040 
ALP > 101 U/L 96 (51) 2.15 1.50    3.06 < 0.01 2.31 1.59   3.36 <0.01 
CRP > 10mg/L 101(53) 1.99 1.39    2.85 <0.01 
Creatinine > 74μmol/L 95 (50) 0.93  0.65    1.31 0.67 
Bilirubin > 9 mmol/L 92 (49) 1.06 0.75    1.51 0.73 
ECOG PS: 2  41 (22) 1.26 0.82    1.93 0.30 
KPS 70 or worse 46 (24) 1.61 1.08    2.41 0.02 
Body Weight < 76 95 (52) 1.31 0.92    1.88 0.13 
QOL:
CES-D > 14 95 (51) 1.01 0.71    1.44 0.95 
FACT-F >23 93 (50) 1.04 0.73    1.47 0.84 
HADS-A > 5 95 (51) 1.06 0.75    1.51 0.74 
HADS-D > 5 80 (43) 1.10 0.77    1.57 0.61 
*Cutoffs for continuous variables were chosen to divide the sample into equal-sized groups. 
†When calculating hazard ratios the expected best was the reference group (i.e., worst vs. best). 
The adjusted hazard ratio for treatment effect (sertraline vs. placebo) changed little 
compared to the unadjusted result(adjusted HR = 1.31 [95% CI: 0.90-1.91], p = 0.15). 
Other factors which were associated with significant increased risk of death in 
multivariable analysis included: patients with liver or brain metastatic disease had 64% 
increased risk of death; patients with lung as the primary site had 2.4 times the risk of 
dying compared to those with other primary sites; patients on opiods or having 
chemotherapy at baseline had 2 times the risk of death compared to patients not on these 
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treatments. Lastly patients with lower lymphocytes (<1.5 x 109/L) or higher ALP ( >101 
U/L) were associated with 50% and 131% increased risk respectively compared to 
patients in the other category.
Table 6 contains information for the 128 patients who died regarding the circumstances 
of their death and treatment received prior to the death. There was no difference in the 
number of deaths due to cancer progression between treatment groups (65 in sertraline 
group vs. 59 in placebo group, p = 0.8) or in the number of deaths occurring earlier than 
expected (6 vs. 6, p = 1.0). 
However, fewer patients on sertraline than placebo were considered by their clinicians to 
have evidence of progressive cancer in the 3 months before death (88% vs. 98%, p=0.03). 
Half of the deaths in each group occurred while taking study drug or within 30 days of 
stopping it (34 in sertraline vs. 31 in placebo, p = 0.6). There were no differences in the 
rates of patients who received chemotherapy, radiotherapy or opioids since their last 
assessment prior to their death. No suicides were documented or suspected. 
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Table 6: Death timing, attribution and relation to treatments 
Sertraline
(%)
Placebo
 (%) 
P-value*
All deaths, N 67 61
Death attributed to: 
Cancer 65 (97) 58 (95) 0.8
Anticancer treatment 0 0
Cancer and anticancer treatment 0 1 (2) 
Other cause 2 (3) 2 (3) 
Place of death: 
Hospital 36 (55) 37 (63) 0.63
Hospice 12 (18) 9 (15) 
Nursing home 1 (1) 2 (3) 
Home 13 (20) 8 (14) 
Other 0 0
Unknown 4 (6) 3 (5) 
Disease progression evident: 
Yes 58 (88) 58 (98) 0.03
No 6 (9) 0
Unknown 2 (3) 1 (2) 
Died earlier than expected: 
Yes 6 (9) 6 (10) 1.0
No 57 (86) 53 (88) 
Unknown 3 (5) 1 (2) 
Relationship to study drug: 
On study drug 24 (36) 18 (30) 0.60
30 days or less after stopping drug 10 (15) 13 (21) 
>30 days after stopping study drug 33 (49) 30 (49) 
Relationship to anticancer treatment: 
Chemotherapy since last assessment 8 (15) 9 (20) 0.60
Radiotherapy since last assessment 5 (9) 4 (9) 1.0
Relationship to supportive treatment: 
Regular opioids since last assessment 27 (68) 21 (70) 1.0
*Fisher’s exact test, unknown category excluded from calculation of p-value. 
Per-protocol analysis: This analysis includes only those patients who received treatment 
so that a valid assessment can be made to ascertain whether the treatment is related to the 
occurrence of adverse events. For example, the active treatment may have side effect 
such as nausea. So, the per-protocol analysis includes only patients who took treatment so 
that this can be assessed accurately.  
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Table 7 details the frequency and severity of adverse events experienced by the patients 
in the two treatment groups. The frequency and severity of most adverse events were 
similar in both groups. Grade 2 or 3 vomiting was more common in sertraline group, 
whereas, mild oedema was more common in the placebo group. 
Table 7: Adverse events: Worst grade experienced*† (%) 
Sertraline (n = 91) Placebo (n = 94) P-value‡
Grade 0 1 2 3 4 0 1 2 3 4
Nausea 39 21 23 8 0 35 37 15 7 0 0.81
Vomiting 59 11 12 9 0 62 22 8 2 0 0.42
Diarrhoea 63 16 6 6 0 65 20 5 4 0 0.87
Constipation 51 24 8 6 2 43 32 17 2 0 0.29
Hyponatremia 77 12 0 2 0 73 17 0 4 0 0.22
Oedema 74 10 6 1 0 62 24 7 1 0 0.03
Thrombosis/ 
embolism 
87 1 0 3 0 89 0 0 3 2 0.74
Headache 62 19 8 2 0 68 17 9 0 0 0.52
Confusion 75 9 4 2 1 82 9 3 0 0 0.31
Seizures 91 0 0 0 0 93 1 0 0 0 0.33
Depressed level of 
consciousness
75 11 3 2 0 77 8 6 2 1 0.84
*NCI CTC V2 grading scale 
†Using events reported during assessments performed up to the assessment following the treatment 
termination date plus 30 days. 
‡ Mann-Whitney U test 
Table 8 details the worst toxicity levels reached for patients in each treatment group. 
Only some minor differences were observed between the sertraline and placebo group. 
For example, for creatinine, more patients in the sertraline group experienced grade I or II 
toxicity; but this difference is not statistically significant.  
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Table 8: Worst toxicity levels reached*† (%)
Sertraline Placebo P-value‡
Blood test 0 1 2 3 4 0 1 2 3 4
WCC 67 8 10 3 1 70 10 10 4 0 0.95
Lymphocytes 35 9 28 17 0 39 7 36 12 0 0.61
Hemoglobin 21 42 22 4 0 25 44 19 5 1 0.67
Platelets 60 25 2 2 0 65 20 6 3 0 0.99
Creatinine 67 14 7 0 0 79 13 2 0 0 0.15
Bilirubin 76 6 4 0 0 75 8 5 5 0 0.13
Serum albumin 46 19 20 2 0 36 32 22 3 0 0.15
Serum sodium§ 47 35 0 6 0 49 34 0 10 1 0.64
AST 58 21 5 0 0 64 15 5 6 1 0.83
ALT 64 20 2 2 0 73 15 2 2 1 0.42
JGT 32 22 17 13 3 31 20 22 16 4 0.43
ALP 41 31 10 6 0 38 34 15 6 0 0.41
*NCI CTC V2 grading scale 
†Using laboratory measurements (up to 52 week assessments only) performed up to the treatment 
termination date plus 30 days and additionally the first laboratory test results done after this date. 
‡ Mann-Whitney U test 
§Grading system excludes grade 2. 
Figure 3 shows the Kaplan-Meier curve for time to treatment discontinuation according 
to randomised treatment. Sertraline was discontinued earlier and more often than was 
placebo. The HR for discontinuing treatment for sertraline is 1.44 compared to placebo 
[95% CI: 1.02 to 2.04, log-rank p value = 0.04]. 
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Figure 3: Time on study drug 
Logrank test: p=0.04
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Conclusionȱ
Sertraline had no significant effect on depression (assessed by CES-D, HADS-D, Pt-
DATA-Form), anxiety (assessed by HADS-A, Pt-DATA-A) or fatigue (assessed by 
FACT-F, Pt-DATA-F).
The interim analysis suggested a statistically significant (2p=0.04) adverse effect of 
sertraline on overall survival. This effect became less apparent with more patients and 
follow-up; as in the final analysis there was no longer a significant difference in survival 
time between the two treatment arms. Required sample size for the study was 400 
patients (200 per group) to give over 90% power. Where as the interim analysis was 
conducted on 150 patients. Consequently this finding in the interim analysis was most 
likely a chance finding or due to chance imbalances between the two treatment arms. The 
estimated effect of sertraline on overall survival, from the final analysis, in this trial 
might have been biased by early stopping of the trial; the true effect would probably even 
be closer to no effect. 
The difference in overall survival between groups at the first interim analysis did not 
reach the pre-specified rule for stopping (2p=0.003), but the independent safety and data 
monitoring committee believed that greater prudence was warranted for possible harm 
than for benefit, since survival time was significantly shorter (at the Į = 0.05 level of 
significance) in the sertraline arm. As a result the trial was suspended pending additional 
follow-up. The trial was closed because of futility reasons; there was no chance of a 
clinically important benefit of sertaline on QoL or survival. It was not closed because of 
concerns about adverse effects on survival or any harm. There was no chance of getting a 
significant benefit of treatment even if the trial continued until the original sample size 
was achieved. Also the recruitment rate was unacceptably slow.
There was no evidence to suggest that sertraline was associated with adverse effects that 
would decrease survival. Sertraline should continue to be used in patients with major 
depression however there is no indication for patients with minor depression. 
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The major strengths of the study were: double-blind, randomized design; use of validated 
outcome measures and enrolment of a broad cross-section of patients with advanced 
cancer. Compliance with completion of questionnaires (low missing data) and with study 
treatment was excellent. It was a high quality trial with very complete data. Results are 
generalisable to patients with all kinds of cancer. Therefore important benefits of 
sertraline in these patients are unlikely to have been missed out.
Imprecise definition of the study population was an important limitation of the study. The 
diagnosis of major depression was the main exclusion criteria, but this judgment was 
arbitrary and left to the responsible oncologist. But this is the reality in clinical practice 
anyway.
The lowest recommended dose of sertraline was used to avoid side effects. We doubt that 
a higher dose or a different anti-depressant may have been more effective. However this 
possibility cannot be ruled out.
We postulated that improvement in aspects of QoL (depression, anxiety and fatigue) 
would increase survival. This remains untested because symptoms of QoL were not 
improved by this trial . This causal assumption may be flawed anyway. Earlier small 
trials which demonstrated this were not confirmed by larger trials. 
The study did not find any significant effect of improving depression in cancer patients 
due to the treatment. The study needed 440 patients to have enough power to detect a 
clinically significant benefit of sertraline on QoL. However, analysis based on the 189 
patients randomised revealed that the trial should be closed due to futility reasons as there 
was no chance of obtaining a clinically significant effect. There is another issue with the 
definition of major depression.  
As per the general principle, if a treatment really works for improving an outcome, the 
effect would be more obvious if the study is conducted on patients with severe illness. 
Despite the possible inclusion of patients with major depression into the trial, due to the 
arbitrary nature of the exclusion criteria, there was still no benefit demonstrated by 
sertraline on improving quality of life.  
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Abbreviationsȱ
HR  Hazard Ratio 
QoL  Quality of life  
CES-D Centre for Epidemiologic Studies- Depression  
HADS Hospital Anxiety and Depression Scale 
FACT Functional Assessment of Cancer Therapy 
Pt DATA Patient Disease and Treatment Assessment Form 
KPS  Karnofsky Performance Status 
ECOG  Eastern Cooperative Oncology Group 
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